P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.

Bibliographic Details
Main Authors:	Daniele Sannipoli, Gariazzo Camilla, Francesca Farina, Elisa Diral, Alessandro Bruno, Daniela Clerici, Sarah Marktel, Luca Canziani, Gloria Catalano, Paolo Fiore, Chiara Oltolini, Patrizia Rovere Querini, Consuelo Corti, Fabio Ciceri, Giordano Vitali, Maria Teresa Lupo-Stanghellini
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000973164.50042.3f

Similar Items

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
by: Francesca Farina, et al.
Published: (2023-08-01)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
by: Francesca Farina, et al.
Published: (2023-08-01)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
by: D. wang, et al.
Published: (2022-06-01)

RIC VS MAC IN ALLO-HSCT FOR CHILDHOOD MYELODYSPLASTIC SYNDROME
by: Elena Morozova, et al.
Published: (2023-12-01)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
by: Francesca Farina, et al.
Published: (2022-07-01)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
by: Shengnan Zhou, et al.
Published: (2023-08-01)

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
by: Elisa Diral, et al.
Published: (2023-08-01)

Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
by: Carmine Liberatore, et al.
Published: (2021-04-01)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
by: Luxiang Wang, et al.
Published: (2023-07-01)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
by: Wen-hui Wang, et al.
Published: (2023-01-01)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
by: J. M. Cerezo-Martin, et al.
Published: (2022-06-01)

Allo-HSCT with TBI-based preconditioning for hepatosplenic T-cell lymphoma: two case reports and systematic review of literature
by: Can Chen, et al.
Published: (2024-01-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
by: T. Ueda, et al.
Published: (2024-01-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
by: Zhangjie Chen, et al.
Published: (2023-03-01)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
by: Maria Teresa Lupo-Stanghellini, et al.
Published: (2021-11-01)

CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
by: M. I. Zaraiski
Published: (2014-07-01)

Application of metagenomic next-generation sequencing in the clinical diagnosis of infectious diseases after allo-HSCT: a single-center analysis
by: Hailong Yuan, et al.
Published: (2024-03-01)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
by: Zhangjie Chen, et al.
Published: (2023-08-01)

Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
by: Jinhua Ren, et al.
Published: (2023-03-01)

Monocytes in allo-HSCT with aged donors secrete IL-1/IL-6/TNF to increase the risk of GVHD and damage the aged HSCs
by: Xia Li, et al.
Published: (2024-03-01)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
by: Shiyu Deng, et al.
Published: (2023-08-01)

Abnormalities by Multicolor Flow Cytometry for Detection of Minimal Residual Disease in Recipients of Allo-HSCT Originating from Donors: A Cohort Study
by: Hui Wang, et al.
Published: (2023-03-01)

How Tycho Brahe’s recordings in 1572 support SN 1572 as a type I(a) supernova
by: Tobias C. Hinse, et al.
Published: (2023-09-01)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
by: Ming Sun, et al.
Published: (2023-08-01)

Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
by: Qianwen Xu, et al.
Published: (2023-10-01)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
by: Bu X, et al.
Published: (2023-08-01)

The question of paper in Os Lusíadas, 1572
by: B Penafiel, A
Published: (2020)

The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center
by: Junyan Gao, et al.
Published: (2022-05-01)

Allò mental, representació d'allò somàtic?
by: Octavi Fullat
Published: (1981-03-01)

Dental consensus on HSCT – Part II: dental Care during HSCT
by: Marcella Ferreira Gobbi, et al.
Published: (2023-07-01)

Dentistry consensus on HSCT – Part III: Special topics – Dentistry on HSCT
by: Paulo Sérgio da Silva Santos, et al.
Published: (2023-07-01)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
by: M. chen, et al.
Published: (2022-06-01)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
by: Valeria Ferla, et al.
Published: (2022-08-01)

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies
by: Giovanni Mori, et al.
Published: (2024-01-01)

Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
by: Xing-yu Cao, et al.
Published: (2023-07-01)

Dangers resulting from DNA profiling of biological materials derived from patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with regard to forensic genetic analysis
by: Renata Jacewicz, et al.
Published: (2016-07-01)

Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2)
by: Enrico Morello, et al.
Published: (2022-08-01)

The hospitals of London: administration, refoundation, and benefaction, c.1500-1572
by: Daly, CT
Published: (1993)

C. Rooze-Stouthamer, Hervorming in Zeeland (ca.1520-1572)
by: A.Th. van Deursen
Published: (1998-01-01)

J. van Herwaarden, Geschiedenis van Dordrecht tot 1572
by: M. Boone
Published: (1999-01-01)